Securities Class Action Filed Against Hims & Hers Adds to Legal Burden

What happened

On October 13, 2026, law firm Bronstein, Gewirtz & Grossman announced a securities class action against Hims & Hers, alleging investor harm from misleading statements, with a lead plaintiff deadline of November 1, 2026. The suit follows the July 2026 FTC and state action over privacy, billing, and cancellation practices, which Hims disclosed in its 10-Q and for which it accrued approximately $60 million. The new filing extends legal exposure from regulatory and consumer claims to securities fraud claims, adding potential financial and reputational costs not yet reflected in the company's reserve. However, the announcement is a law firm solicitation, not a court finding, and such class actions often fail to survive early motions; investors should treat the allegations as unproven. The development still increases uncertainty around the timing and magnitude of legal resolutions, potentially distracting management during a critical operational turnaround.

Implication

The securities class action adds another layer of legal risk to Hims, which already faces FTC/state litigation and a consumer class action, suggesting total legal costs could exceed the current $60 million accrual. While class action complaints often include boilerplate allegations, the securities suit could gain traction if it identifies specific misleading statements about subscriber growth, gross margin, or compliance that were later contradicted by the FTC action or quarterly results. Management will need to divert resources to litigation, potentially delaying focus on improving gross margin and customer acquisition efficiency, which are critical for the Q3-Q4 2026 turnaround. For investors, the news reinforces the existing downside scenario where legal remedies impair the demand engine, but it does not change the core operating thesis that margin recovery and subscriber retention are the primary value drivers. Until there is clarity on the scope of potential damages or injunctive relief, the stock may trade with a wider risk discount, and we maintain the WAIT rating with a trim above $37 and attractive entry at $24.

Thesis delta

The investment thesis already incorporated regulatory and litigation risk via the FTC case and $60 million accrual. The securities class action adds a similar but distinct claim for damages, potentially increasing the total legal liability beyond the current reserve. However, it does not alter the fundamental question of whether branded GLP-1 economics can restore gross margin; thus the thesis remains WAIT, but the bear case probability may edge slightly higher.